These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. An optimal three-stage design for phase II clinical trials. Ensign LG; Gehan EA; Kamen DS; Thall PF Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706 [TBL] [Abstract][Full Text] [Related]
29. Minimax and admissible adaptive two-stage designs in phase II clinical trials. Shan G; Zhang H; Jiang T BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595 [TBL] [Abstract][Full Text] [Related]
30. Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. Yu Z; Wu L; Bunn V; Li Q; Lin J Ther Innov Regul Sci; 2023 Jul; 57(4):823-838. PubMed ID: 36871111 [TBL] [Abstract][Full Text] [Related]
31. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach. Cellamare M; Sambucini V Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
34. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials. Kim J; Schell MJ Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960 [TBL] [Abstract][Full Text] [Related]
35. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Pond GR; Abbasi S Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687 [TBL] [Abstract][Full Text] [Related]
36. [Research design for patient selection in clinical trials phase II]. Kramar A; Potvin D; Hill C Rev Epidemiol Sante Publique; 1996 Aug; 44(4):364-71. PubMed ID: 8927779 [TBL] [Abstract][Full Text] [Related]
37. Re-formulating Gehan's design as a flexible two-stage single-arm trial. Grayling MJ; Mander AP BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398 [TBL] [Abstract][Full Text] [Related]
38. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship. Guo B; Li Y BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481 [TBL] [Abstract][Full Text] [Related]
39. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712 [TBL] [Abstract][Full Text] [Related]
40. A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Howard DR; Hockaday A; Brown JM; Gregory WM; Todd S; Munir T; Oughton JB; Dimbleby C; Hillmen P Trials; 2021 Jan; 22(1):38. PubMed ID: 33419469 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]